S_unmary Wild-type as well as vanrant oestrogen receptor (ER) mRNAs with exon 5 and 7 deleted were identified in a panel of human breast tumour cell lines by reverse transcriptase-polymerase chain reaction followed by dideoxynucleotide sequence analysis, and then quantitated by ribonuclease protection analysis. Kumar et al., 1987; Ponglikitmongkol et al., 1988) . In addition, numerous subdomains are also located throughout the ER, including those involved in transcription activation, receptor dimerisation, nuclear localisation and binding of heat shock proteins (Kumar et al., 1987; Green and Chambon, 1991) .
The oestrogen receptor (ER) is a member of the steroid receptor superfamily, a group of intracellular transcription factors whose functions are regulated by binding their cognate ligand (Evans et al., 1988) . The presence of ER, as determined by ligand-binding analysis, has been established as an important prognostic indicator in the treatment of breast cancer, predicting both a decreased risk of relapse and improved disease-free survival (Benner et al., 1988) . Perhaps more importantly, ER is a strong predictor of tumour responsiveness to endocrine therapy (McGuire et al., 1975) . Oestrogen receptor-positive breast tumours are more likely to respond to hormonal (tamoxifen) therapy, having a response rate approaching 70%, while ER-negative tumours have a hormone response rate of only 10% (Edwards et al., 1979) . It has also been demonstrated that steroid receptors, including ER, possess discrete functional domains for ligand binding, DNA binding and trans-activation. The DNA-binding domain of the ER is encoded by exons 2 and 3 of the ER gene, while the ligand-binding domain is encoded by exons 4-8 (Walter et al., 1985; Kumar et al., 1987; Ponglikitmongkol et al., 1988) . In addition, numerous subdomains are also located throughout the ER, including those involved in transcription activation, receptor dimerisation, nuclear localisation and binding of heat shock proteins (Kumar et al., 1987; Green and Chambon, 1991) .
We have recently identified variant ER mRNA transcripts containing precise deletions of exon 3, 5 or 7 in breast tumours classified as ER-negative progesterone receptor (PgR) positive or ER positive/PgR negative by ligandbinding analysis (Fuqua et al., 1991 (Fuqua et al., , 1992a McGuire et al., 1992) . We have also observed the exon 5 deletion variant (A5) ER mRNA in the ER-positive MCF-7 and the ERnegative BT-20 human breast tumour cell lines (Castles et al., 1993) , while others have identified deletions of exons 4 and 7 in MCF-7 cells (Koehorst et al., 1993; Pfeffer et al., 1993) .
Previous studies by our group (Fuqua et al., 1991; 1992a; Castles et al., 1993) tional regulatory activity. In this same expression system, we also demonatrated that an exon 7 deletion variant (A7) ER mRNA was translated into a variant receptor which interfered with the DNA binding and the subsequent trans-activation capacity of wild-type ER (Fuqua et al., 1992a) . In addition to the MCF-7 and cell lines, the T47D breast tumour cell line also expresses a number of ER mRNA variants, including frameshift mutations which could potentially encode receptors truncated at the DNA-binding and/or hormone-binding domains, as well as variants containing deletions of exon 2, 3 or 7 (Graham et al., 1990; Wang and Miksicek, 1992; Fuqua et al., 1993) .
It is clear from our earlier studies (Fuqua et al., 1992a) (Chen and Seeburg, 1985) and both strands were sequenced (Sequenase version 2.0, United States Biochemicals, Cleveland, OH, USA) using SP6 and T7 promoter primers (Sanger et al., 1977) (nucleotides 1389-1527) deleted. The A7 probe was generated using a cDNA clone containing portions of exons 6 and 8 (nucleotides 1542-2031) but with exon 7 (nucleotides 1662-1845) deleted. Radiolabelled variant ER antisense cRNA probe was generated using a Riboprobe Gemini II Core System (Promega) and purified by polyacrylamide gel electrophoresis. Hybridisation of 1 x 106c.p.m. of labelled probe with sample RNA and subsequent digestion with RNAses A and T, were carried out using an RPA kit II (Ambion, Austin, TX, USA). The samples were heated at 85°C for 5 mi, loaded onto a 6% polyacrylamide/8 M urea gel and ekctrophoresed at 1200 V for 4 h. Gels were dried and exposed to Kodak XAR film at -70°C for 18-48h.
The numbers generated by densitometric analysis were corrected to account for the molar differences in size between the fully protected variant fragments and the partially protected wild-type fragment. The overall amount of radioactivity (probe) bound to the partially protected wild-type fragment identified in Figure 3 was approximately 20% less than that bound to the full-length protected fragment of the A5 variant transcript. Similarly, the numbers generated by densitometric analysis of the A7 assays were corrected to account for the molar differences in size between the two protected fragments. The partially protected wild-type fragment contained approximately 40% less radioactivity than the full-length protected fragment of the A7 vanrant transcript.
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RT-PCR amplification, cloning and sequence analysis Total cellular RNA from the ER-positive MCF-7 and MDA-MB-361 cell lines and the ER-negative MDA-MB-330 and MDA-MB-231 cell lines was reverse transcribed and cDNA fragments from nucleotides 1142-1580 of the ER mRNA amplified by PCR using the primers HBIO and HB11. Amplified products were then separated on a 5% polyacrylamide gel. Similar to what has been previously demonstrated in some primary breast tumours (Fuqua et al., 1991) , all of these breast tumour cell lines except the MDA-MB-231 line expressed two amplified products: a larger 438 bp product which corresponds in size to the expected wild-type ER product and a smaller 300 bp variant band ( Figure la) . Dideoxynucleotide sequence analysis of the larger fragment from MCF-7, MDA-MB-361, BT-20 and MDA-MB-330 cells confirmed sequences established for the human ER (Ponglikitmongkol et al., 1988) , while the smaller variant fragment was found to contain wild-type sequences for exons 4 and 6 with exon 5 deleted (Castles et al., 1993) .
Reverse transcriptase-polymerase chain reaction amplification of total RNA from the four cell lines mentioned above was also performed using the primers HB18 and ERY6 to generate cDNA fragments from nucleotides 1553-2042 of the ER mRNA (Figure lb) . The MCF-7, MDA-MB-361 and MDA-MB-330 cell lines expressed two amplified products: a larger 489 bp product which correlated with the expected size of the wild-type ER product and a smaller 305 bp variant transcript. Clones from each of these cell lines containing the 489 bp product were sequenced and shown to correspond to the wild-type sequence for the ER. A representative sequence from the MDA-MB-330 cell line is shown in Figure 2 . Sequence analysis of the cloned 305 bp product from MDA-MB-330 (Figure 2) Further analysis revealed that differences in the expression levels of the ER vanrants among the cell lines were more pronounced for the ratio of the A5 variant to wild-type ( Figure 5 ) than for A7 to wild type. For example, in the MCF-7 cell line ( Figure 5, Table I ), the wild-type ER mRNA accounted for over 57% of the ER transcripts, while the A5 variant accounted for 39% and the A7 variant less than 4% of the total ER mRNA transcripts. In the weakly ERpositive MDA-MB-361 cells, the A5 variant accounted for 51% of the ER mRNA transcripts, the wild-type accounted for 34% and the A7 vanrant 17% of the total ER mRNA species (Table I) 1  41  47  12  MDA-MB-361  41  51  7  MDA-MB-134  34  41  25  BT-474  41  44  15  T47Dco  39  47  14  BT-20  8  68  24  MDA-MB-330  27  58  15  MDA-MB-435S   --- MDA-MB 453
Note that in some cell lines, such as MCF-7. the wild type was the predominant transcript, while in other cell lines, such as MDA-MB-361 and BT-20, the A5 deletion variant was the predominant transcript. Samples were normalised to the loading control. These data are based on the mean of three assays ± s.e.
were made by subtracting A5 or A7 levels from the smaller fragment in the parallel assay with the other probe.
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We report here that a number of human breast tumour cell lines express ER mRNA variants which contain precise deletions of exons S and/or 7. Several ER-positive cell lines as well as some ER-negative cell lines were found to contain varying levels of both wild-type and the two ER variant transcripts. These cell lines include the ER-positive MCF-7, ZR-75-1, MDA-MB-134 and MDA-MB-361 as well as the ER-negative BT-20, MDA-MB-330, BT474 and T47Dco cell lines. Some ER-negative cell lines, including MDA-MB-231, MDA-MB-435s, MDA-MB-453 and Hs578t, failed to express any detectable levels of ER and mRNA.
We have previously identified and characterised the A5 variant ER transcript in the ER-positive MCF-7 and ERnegative BT-20 cell lines (Fuqua et al., 1991; Castles et al., 1993) . This variant transcript encodes a transcriptionally active, dominant-positive variant ER protein. According to our RNAse protection analyses, this variant transcript is the predominant ER mRNA species expressed in the ER-positive MDA-MB-361, MDA-MB-134 and ER-negative BT-20 and MDA-MB-330 cell lines, accounting for 51%, 68%, 41% and 58%, respectively, of the total ER mRNA. We have also previously identified (Fuqua et al., 1992a) in breast tumour specimens a A7 ER mRNA variant that encodes a dominantnegative receptor which interferes with the ability of the wild-type receptor to activate gene transcnption in a yeast reporter assay system. This particular variant ER transcript, along with other variants lacking exons 2 or 3, has been previously identified in the ER-positive T47D cell line (Wang and Miksicek, 1992) , as well as in conjunction with a deletion of exon 4 in MCF-7 cells (Koehorst et al., 1993) .
The coexpression of ER mRNA variants with the wild type is in agreement with earlier reports examining breast tumour specimens (Fuqua et al., 1991 (Fuqua et al., , 1992a Zhang et al., 1993) and the T47D, ZR-75-1, and MCF-7 cell lines (Wang and Miksicek, 1992; Koehorst et al., 1993) . However, based on RNAse protection analysis, the ratio of expression of the A5 and A7 mRNA vanrants to each other as well as to the wild-type ER transcript differed among the cell lines examined. This can also be observed in panels of ER-positive/PgRpositive and ER-positive/PgR-negative breast tumours (SAW Fuqua, unpublished data) . In cell lines such as the ERpositive MCF-7 cell line (Figure 5,  (Fuqua et al., 1991 (Fuqua et al., , 1992a Castles et al., 1993) . Both the A5 and A7 variant proteins when expressed in yeast are truncated forms of the ER, with each variant missing a portion of the hormone-binding domain as well as the dimerisation and AF-2 domains located in the E region of the ER (Fawell et al., 1990) . Since the A5 variant is the predominant ER mRNA isoform in the BT-20 cell line (Castles et al., 1993) , which is ER negative by ligand-binding analysis, and since Fuqua et al. (1992b) have shown that, when expressed in MCF-7 cells, this variant is able to confer hormone independence and tamoxifen resistance, it is possible that expression of this variant may contribute to the hormone indepenent proliferation of the BT-20 and MDA-MB-330 cells.
The A7 ER variant has been shown, by our group, to act in a dominant-negative manner, apparently dimerising with the wild-type receptor to form an inactive heterodiner (Fuqua et al., 1992a) . This variant is expressed at higher levels in the MDA-MB-134 cell line than in other ERpositive cell lines. It is interesting to note that this cell line, although ER positive by ligand binding, is not induced to express PgR in response to oestrogen stimulation (data not shown) (Reiner et al., 1986) . In addition, this cell line also expresses, as detrmined by RNAse protection analysis, a partially protected fragment of intermediate size between the wild-type and the A5 transcript. The exact nature of this partially protected fragment has not been fully characterised so far. Considering the high level of A7 expression in this cell line, it is tempting to speculate that elevated levels of this variant may play a role in the lack of PgR induction by oestradiol, although oestrogen-induced proliferation is not inhibited in these cells. The low-level constitutive expression of PgR in these cells might then be due to. gene activation by the constitutively active truncated A5 ER variant. This variant would not be expected to dimerise with the A7 variant since it is truncated and missing its dimerisation domain. Further studies to characterise these variant ERs, such as analysis of DNA-binding properties, will be needed to determine the true clinical significnce of such variants. The coexpression of the A5 and A7 variant transcripts with the wild-type message in both ER-positive and ER-negative breast cancer cell lines may simply be a reflection of the cancerous state of these cells. However, this is probable not the case since these and other ER mRNA variants have been identified in normal/non-malignant tissues such as the uterus and brain (Koehorst et al., 1993) . Thus, they appear to be naturally occurring splicing variants which may play a role in the development or normal function of some oestrogenresponsive tissues. It is possible that the overexpression of such variants in relation to the wild-type ER might be related to the development of a malignant phenotype or to hormone resistance m some breast tumours. Given the potential biological action of these ER variants, it is probably that their differential expression may be an important factor in modulating the overall oestrogen responsiveness of various tissues as well as the expression of oestrogen responsive genes.
